Skye Bioscience 과거 수익 실적

과거 기준 확인 0/6

Skye Bioscience의 수입은 연평균 -50.8%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 증가했습니다(19.3%).

주요 정보

-50.8%

수익 성장률

-10.0%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	n/a
자기자본 수익률	-28.0%
순이익	n/a
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11

수익 및 비용 분석

Skye Bioscience 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGM:SKYE 수익, 비용 및 수입 (USD Millions )
날짜	수익	G+A 비용	R&D 비용
30 Sep 24	-21	11	13
30 Jun 24	-42	13	9
31 Mar 24	-37	10	7
31 Dec 23	-38	8	6
30 Sep 23	-43	13	6
30 Jun 23	-21	12	6
31 Mar 23	-22	13	6
31 Dec 22	-19	12	6
30 Sep 22	-12	6	6
30 Jun 22	-11	6	4
31 Mar 22	-9	5	4
31 Dec 21	-9	5	3
30 Sep 21	-8	5	2
30 Jun 21	-7	4	2
31 Mar 21	-6	4	2
31 Dec 20	-7	4	2
30 Sep 20	0	5	2
30 Jun 20	-4	4	2
31 Mar 20	13	5	3
31 Dec 19	1	4	2
30 Sep 19	-10	4	2
30 Jun 19	-7	4	1
31 Mar 19	-26	4	1
31 Dec 18	-19	4	0
30 Sep 18	-14	4	0
30 Jun 18	-12	4	0
31 Mar 18	-10	4	0
31 Dec 17	-4	4	0
30 Sep 17	-5	4	0
30 Jun 17	-5	4	0
31 Mar 17	-4	4	1
31 Dec 16	-4	4	1
30 Sep 16	-3	4	1
30 Jun 16	-3	4	1
31 Mar 16	-6	4	0
31 Dec 15	-5	4	0
30 Sep 15	-6	5	0
30 Jun 15	-6	5	0
31 Mar 15	-4	3	0
31 Dec 14	-3	3	0
30 Sep 14	-1	1	0
30 Jun 14	0	0	0
31 Mar 14	0	0	0

양질의 수익: SKYE 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SKYE 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SKYE 은(는) 수익성이 없으며 지난 5년 동안 연간 50.8% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 SKYE 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SKYE 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: SKYE 현재 수익성이 없기 때문에 마이너스 자본 수익률( -28.02% )을 갖습니다.

Skye Bioscience 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Recent updates

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor

Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

High number of new directors

Skye Bioscience, Inc. announced that it has received $40 million in funding from 5AM Venture Management, LLC

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Skye Bioscience, Inc. announced that it has received $49.99101 million in funding

Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding

Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye Bioscience, Inc. Announces Board Appointments

New major risk - Share price stability

Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors

Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma

Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board

Skye Bioscience, Inc. Appoints Chris Twitty as Chief Scientific Officer

Skye Bioscience, Inc. (OTCPK:SKYE) completed the acquisition of Emerald Health Therapeutics, Inc. (CNSX:EMH) from Emerald Health Sciences Inc. and others.

Skye Bioscience, Inc. Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. Updates Phase 1 Timeline

Skye Bioscience, Inc. Announces Resignation of Jim Heppell as A Member of Board of Directors, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee

Skye Bioscience, Inc. (OTCPK:SKYE) entered into a definitive agreement to acquire Emerald Health Therapeutics, Inc. (CNSX:EMH) for CAD 21.7 million.

Skye Bioscience, Inc. Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience, Inc. Reports Potential Neuroprotective Benefit of SBI-100 in Preclinical Glaucoma Model

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, Both as Combination and Single Agent, in Preclinical Study

Skye Bioscience, Inc. Announces Board Appointments

Emerald Bioscience Inc., Annual General Meeting, Jan 28, 2021

Emerald Bioscience Inc. Provides an Update on Progress across its Product Pipeline, including adjusted clinical milestones

Emerald Bioscience Inc. Announces Changes in Principal Financial Officer

Emerald Bioscience Inc. Announces Executive Changes

Emerald Bioscience Inc. has completed a Composite Units Offering in the amount of $6.939667 million.

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기